ArticleAmerican journal of respiratory and critical care medicine2022
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.Critical care (London, England) · 2023Trial
- Ex Vivo Traceability Platform for Phospholipoproteomic Formulations: Functional Evidence Without Clinical Exposure.Biomedicines · 2025Article
- Surviving COVID-19: patients' experiences of care and path to recovery.International journal of qualitative studies on health and well-being · 2024Article
- Patients Hospitalized With Coronavirus Disease 2019: A Diverse Population.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial.EClinicalMedicine · 2023Article
- Outcomes from COVID-19 Clinical Trials in Hospitalized Patients: Seeking the Truth That Matters.American journal of respiratory and critical care medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
30 authors at 19 institutions in 6 countries.
David J DouinDepartment of Anesthesiology.
Lianne SiegelDivision of Biostatistics, School of Public Health.
Greg GranditsDivision of Biostatistics, School of Public Health.
Andrew PhillipsInstitute for Global Health and.
Neil R AggarwalDivision of Pulmonary Sciences and Critical Care, Department of Medicine, and.
Jason BakerDepartment of Medicine, School of Medicine, and.
Samuel M BrownDivision of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah.ORCID 0000-0003-1206-6261
Christina C ChangThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Anna L GoodmanThe Medical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom.
Birgit GrundSchool of Statistics, University of Minnesota, Minneapolis, Minnesota.
Elizabeth S HiggsNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Catherine L HoughDepartment of Medicine, Oregon Health and Sciences University, Portland, Oregon.
Daniel D MurrayCHIP Center of Excellence for Health, Immunity, and Infections, and.
Roger ParedesHospital Germans Trias i Pujol, Badalona, Spain.
Mahesh ParmarJohn Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.
Sarah PettJohn Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.
Mark N PolizzottoThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Uriel SandkovskyDivision of Infectious Diseases, Baylor University Medical Center, Dallas, Texas.
Wesley H SelfDepartment of Emergency Medicine and.
Barnaby E YoungNational Centre for Infectious Diseases, Singapore.
Abdel G BabikerJohn Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.
Victoria J DaveyUnited States Department of Veterans Affairs, Washington, DC.
Virginia KanInfectious Diseases Section, VA Medical Center, Washington, DC.
Annetine C GelijnsDepartment of Population Heath Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York; and.
Gail MatthewsThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
B Taylor ThompsonDivision of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
H Clifford LaneNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
James D NeatonDivision of Biostatistics, School of Public Health.
Jens D LundgrenCHIP Center of Excellence for Health, Immunity, and Infections, and.
Adit A GindeDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Australian National University · AUNational Institute of Allergy and Infectious Diseases · USRigshospitalet · DKUNSW Sydney · AUBaylor University Medical Center · USGuy's and St Thomas' NHS Foundation Trust · GBHarvard University · USHennepin Healthcare Research Institute · USIcahn School of Medicine at Mount Sinai · USIrsiCaixa · ESMurray State University · USNanyang Technological University · SGOregon Health & Science University · USPulmonary and Critical Care Associates · USUnited States Department of Veterans Affairs · USUniversity of Colorado Denver · USUniversity of Minnesota · USVanderbilt University Medical Center · USWashington DC VA Medical Center · US
Funding
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating CenterOT2HL156812 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI NOLEN, TRACY L, THOMAS, SONIA M · 2020 to 2024
$1270.7MREVISED CAROL ACT IIU01HL088942 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GELIJNS, ANNE CHRISTINE, MOSKOWITZ, ALAN J · 2007 to 2025
$122.6MPathogenesis, Treatment and Prevention of Emerging Infectious DiseasesZIAAI000936 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LANE, CLIFFORD · 2009 to 2025
$6.4MAnesthesiology Mentored Research TrainingT32GM135169 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Susan L Ingram, Vesna Jevtovic-Todorovic · 2021 to 2026
$1.0MMedical Research Council MC_UU_00004/03Medical Research Council MC_UU_00004/04Medical Research Council MRC_UU_12023/23NHLBI NIH HHS OT2 HL156812NHLBI NIH HHS U01 HL088942NIGMS NIH HHS T32 GM135169NIH HHS 1OT2HL156812-01
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19AftercareAgedAntibodies, MonoclonalHumansPatient DischargeSARS-CoV-2Treatment OutcomeAntibodies, MonoclonalCOVID-19monoclonal antibodiesoutcomes assessment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.